Olmesartan/Amlodipino/Hidroclorotiazida Lacer (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipino/Hidroclorotiazida Lacer, is a angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in adults who require multiple mechanisms to control blood pressure. GNH USA supplies Olmesartan/Amlodipino/Hidroclorotiazida Lacer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartan/Amlodipino/Hidroclorotiazida Lacer as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipino/Hidroclorotiazida Lacer is used in the management of hypertension, targeting several physiological pathways that regulate blood pressure. - Hypertension: helps lower systolic and diastolic blood pressure when monotherapy is insufficient. - Hypertensive heart disease: reduces cardiac after‑load and improves ventricular function. - Chronic kidney disease with hypertension: slows progression of renal impairment by controlling systemic pressure. - Stroke risk reduction: contributes to lower incidence of cerebrovascular events in high‑risk patients. - Diabetes‑related hypertension: offers blood‑pressure control without adversely affecting glucose metabolism.

Side effects may occur with any antihypertensive regimen and should be monitored by a healthcare professional.

Common Side Effects: - Dizziness or light‑headedness, especially after the first doses. - Peripheral edema, often noticeable in the ankles. - Headache, mild to moderate in intensity. - Flushing or warmth sensation. - Fatigue or general tiredness. - Increased urination due to the diuretic component.

Serious or Rare Side Effects: - Severe hypotension with fainting. - Acute kidney injury or significant rise in serum creatinine. - Hyperkalemia or electrolyte disturbances. - Angio‑edema involving the face, lips, or airway. - Liver enzyme elevations indicating hepatic stress. - Blood cell abnormalities such as leukopenia or thrombocytopenia.

Patients should be evaluated for contraindications and monitored during therapy. - Pregnancy: avoid use; teratogenic risk especially in the second and third trimesters. - Renal impairment: adjust dosing and monitor kidney function regularly. - Hepatic disease: use with caution; monitor liver enzymes. - Electrolyte balance: check serum potassium and sodium periodically. - Concomitant antihypertensives: may increase risk of excessive blood‑pressure lowering. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Olmesartan/Amlodipino/Hidroclorotiazida Lacer can interact with several drug classes; clinicians should review patient medication lists.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, aliskiren) – risk of renal failure and hyperkalemia. - Potassium‑sparing diuretics or supplements – may cause dangerous hyperkalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin) – increase amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – may blunt antihypertensive effect and affect renal function. - Lithium – increased risk of lithium toxicity. - Antidiabetic agents – may require dose adjustment due to enhanced glucose‑lowering effect. - Alcohol – additive blood‑pressure lowering and dizziness. - Rifampin – may reduce effectiveness of amlodipine.